PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY ROA • Market segmentation by RoA • Comparison by RoA • Parenteral - Market size and forecast 2018-2023 • Oral - Market size and forecast 2018-2023 • Others - Market size and forecast 2018-2023 • Market opportunity by RoA PART 07: MARKET SEGMENTATION BY INDICATION PART 08: MARKET SEGMENTATION BY TECHNOLOGY PART 09: CUSTOMER LANDSCAPE PART 10: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • Americas - Market size and forecast 2018-2023 • EMEA - Market size and forecast 2018-2023 • APAC - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Eli Lilly • Novo Nordisk • Sanofi • Takeda Pharmaceutical • Teva Pharmaceutical PART 15: APPENDIX • Research methodology • List of abbreviations   Exhibit 01: Years in consideration Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: RoA - Market share 2018-2023 (%) Exhibit 19: Comparison by RoA Exhibit 20: Parenteral - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Parenteral - Year-over-year growth 2019-2023 (%) Exhibit 22: Oral - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Oral - Year-over-year growth 2019-2023 (%) Exhibit 24: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Others - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by RoA Exhibit 27: Market share by 2018-2023 (%) Exhibit 28: Customer landscape Exhibit 29: Market share by geography 2018-2023 (%) Exhibit 30: Geographic comparison Exhibit 31: Americas - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Americas - Year-over-year growth 2019-2023 (%) Exhibit 33: EMEA - Market size and forecast 2018-2023 ($ millions) Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%) Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions) Exhibit 36: APAC - Year-over-year growth 2019-2023 (%) Exhibit 37: Key leading countries Exhibit 38: Market opportunity Exhibit 39: Decision framework Exhibit 40: Impact of drivers and challenges Exhibit 41: Vendor landscape Exhibit 42: Landscape disruption Exhibit 43: Vendors covered Exhibit 44: Vendor classification Exhibit 45: Market positioning of vendors Exhibit 46: Eli Lilly - Vendor overview Exhibit 47: Eli Lilly - Business segments Exhibit 48: Eli Lilly - Organizational developments Exhibit 49: Eli Lilly - Geographic focus Exhibit 50: Eli Lilly - Segment focus Exhibit 51: Eli Lilly - Key offerings Exhibit 52: Eli Lilly - Key customers Exhibit 53: Novo Nordisk - Vendor overview Exhibit 54: Novo Nordisk - Business segments Exhibit 55: Novo Nordisk - Organizational developments Exhibit 56: Novo Nordisk - Geographic focus Exhibit 57: Novo Nordisk - Segment focus Exhibit 58: Novo Nordisk - Key offerings Exhibit 59: Novo Nordisk - Key customers Exhibit 60: Sanofi - Vendor overview Exhibit 61: Sanofi - Business segments Exhibit 62: Sanofi - Organizational developments Exhibit 63: Sanofi - Geographic focus Exhibit 64: Sanofi - Segment focus Exhibit 65: Sanofi - Key offerings Exhibit 66: Sanofi - Key customers Exhibit 67: Takeda Pharmaceutical - Vendor overview Exhibit 68: Takeda Pharmaceutical - Business segments Exhibit 69: Takeda Pharmaceutical - Organizational developments Exhibit 70: Takeda Pharmaceutical - Geographic focus Exhibit 71: Takeda Pharmaceutical - Key offerings Exhibit 72: Takeda Pharmaceutical - Key customers Exhibit 73: Teva Pharmaceutical - Vendor overview Exhibit 74: Teva Pharmaceutical - Business segments Exhibit 75: Teva Pharmaceutical - Organizational developments Exhibit 76: Teva Pharmaceutical - Geographic focus Exhibit 77: Teva Pharmaceutical - Segment focus Exhibit 78: Teva Pharmaceutical - Key offerings Exhibit 79: Teva Pharmaceutical - Key customers Exhibit 80: Validation techniques employed for market sizing Exhibit 81: List of abbreviations  

Eli Lilly Novo Nordisk Sanofi Takeda Pharmaceutical Teva Pharmaceutical